more FDA signposts...SRPT...
SRPT is a competitor to BMRN in the DMD space...SRPT has an Adcom next week or so...FDA released briefing documents yesterday and was negative...SRPT down 50% today before Adcom...
..so go back to TST FDA briefing documents when released TST had limited to no price reaction (i believe it had moved briefly from $0.80 to $1.00 on some pumper idiocy about some supposed Japan partnership) ...and TST documents were net-net positive toward MCNA
..regards